Blood coagulation Factor X occupies a central role in the clotting cascade. It can be activated by either Factor VIIa-tissue factor (extrinsic tenase) or by Factor IXa-VIIIa-phospholipid (intrinsic tenase). Once activated, it participates in formation of the prothrombinase complex, composed of Factor Xa (F.Xa) and the cofactor Factor Va (F.Va) on a membrane surface in the presence of calcium ions. The prothrombinase complex catalyzes the conversion of prothrombin to the active serine protease thrombin. Recent work has also established that, in addition to its role in the coagulation cascade, F.Xa serves as a ligand for the cellular receptor Effector Cell Protease Receptor-1 (EPR-1), a membrane- bound protein found on monocytes, lymphocytes, endothelial cells and vascular smooth muscle cells. This observation suggests that F.Xa, like thrombin and protein S, can serve as a link between the coagulation system and other host defense systems such as inflammation and wound repair. The goal of the experiments in this proposal is to determine the molecular sites of interaction between F.Xa and its cofactor F.Va, and between F.Xa and its cellular receptor EPR-1. To carry this out, we will prepare recombinant variants of F.Xa using site-directed mutagenesis and a mammalian expression system. We have recently worked out a multi-step procedure for isolating fully carboxylated rF.Xa from the expression system. Both chimeric proteins (domain exchanges) and point mutations will be synthesized and tested. Choice of mutations for analysis will be based on the defined 3-dimensional structure of F.Xa and on previous experimental findings including work with proteolytic fragments, with synthetic peptides, and with chimeric proteins. Binding to F.Va will be assessed using optical biosensor technology and competitive inhibition assays. To determine sites on F.Xa required for interaction with EPR-1, recombinant variants will be radiolabelled and tested in binding assays to EPR+ HUVEC's and to CHO cells transfected with EPR-1. This work will contribute to our understanding of the molecular interactions by which F.Xa exerts its biological effects in enzyme complexes and through cellular receptors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL048322-07
Application #
2445228
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1992-08-17
Project End
2000-06-30
Budget Start
1997-07-01
Budget End
1998-06-30
Support Year
7
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Whinna, H C; Lesesky, E B; Monroe, D M et al. (2004) Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. J Thromb Haemost 2:1127-34
Arruda, V R; Hagstrom, J N; Deitch, J et al. (2001) Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 97:130-8
Camire, R M; Larson, P J; Stafford, D W et al. (2000) Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide. Biochemistry 39:14322-9
Larson, P J; Camire, R M; Wong, D et al. (1998) Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles. Biochemistry 37:5029-38
Carew, J A; Pollak, E S; High, K A et al. (1998) Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter. Blood 92:1639-45
Wu, S M; Stafford, D W; Frazier, L D et al. (1997) Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. Blood 89:4058-62
Ambrosini, G; Plescia, J; Chu, K C et al. (1997) Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem 272:8340-5
Larson, P J; Stanfield-Oakley, S A; VanDusen, W J et al. (1996) Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa. J Biol Chem 271:3869-76
Pollak, E S; Hung, H L; Godin, W et al. (1996) Functional characterization of the human factor VII 5'-flanking region. J Biol Chem 271:1738-47
Chu, K; Wu, S M; Stanley, T et al. (1996) A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 98:1619-25

Showing the most recent 10 out of 13 publications